Home / Market News / $UTHR
benzinga Corporate Catalyst Impact 55/100 ● positive

RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $708

Oct 8, 2026, 2:58 PM UTC · Primary ticker $UTHR

RBC Capital analyst Lisa Walter reiterated an Outperform rating on United Therapeutics and increased the price target from $677 to $708. This indicates continued analyst confidence in the company's future performance and could lead to a positive, albeit moderate, short-term market reaction for UTHR shares.

RBC Capital's analyst Lisa Walter maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised the price target from $677 to $708. This action signals continued bullish sentiment from a prominent financial institution regarding UTHR's prospects. For traders, this could provide a short-term positive catalyst, as increased price targets often lead to upward pressure on a stock's price. The long-term implications depend on whether the company's fundamentals align with this optimistic outlook, but for now, it reinforces investor confidence. The key opportunity for traders is to potentially capitalize on any immediate positive price movement following this analyst upgrade.

$UTHR positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.